Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents

International Journal of Infectious Diseases

Volumn 16, Issue 12, 2012, Pages

  Schtscherbyna, Annie ^a   Pinheiro, Maria Fernanda Miguens Castelar ^b   Mendonça, Laura Maria Carvalho de ^a   Gouveia, Carla ^a   Luiz, Ronir Raggio ^a   Machado, Elizabeth Stankiewicz ^a   Farias, Maria Lucia Fleiuss de ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Endocrinology Department of Internal Medicine   (Brazil)

Author keywords

Adolescent; AIDS; Body composition; Bone mineral density; DXA; HIV

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PARATHYROID HORMONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BRAZIL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OSTEOLYSIS; VERTICAL TRANSMISSION;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; BONE DENSITY; BONE DISEASES; BRAZIL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR NECK; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LUMBAR VERTEBRAE; MALE; RISK FACTORS;

EID: 84869214262     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.07.019     Document Type: Article

References (39)

1. Patel K., Hernán M.A., Williams P.L., Seeger J.D., McIntosh K., Van Dyke R.B., et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008, 46:507-515.
2. Ministry of Health, Brazil Boletim epidemiológico-AIDS e DST 2007, Ministério da Saúde, Brasília, Brazil.
3. Saavedra J.M., Henderson R.A., Perman J.A., Hutton N., Livingston R.A., Yolken R.H. Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch Pediatr Adolesc Med 1995, 149:497-502.
4. Bolland M.J., Grey A. HIV and low bone density: responsible party, or guilty by association?. IBMS BoneKEy 2011, 8:7-15.
5. Borderi M., Gibellini D., Vescini F., De Crignis E., Cimatti L., Biagetti C., et al. Metabolic bone disease in HIV infection. AIDS 2009, 23:1297-1310.
6. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
7. Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269:729-730.
8. Gordon C.M., Bachrach L.K., Carpenter T.O., Crabtree N., El-Hajj Fuleihan G., Kutilek S., et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008, 11:43-58.
9. Onis M., Onyango A.W., Borghi E., Siyam A., Nishida C., Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007, 85:660-667.
10. Morris N.M., Udry J.R. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 1980, 9:271-280.
11. Dietary reference intakes for calcium and vitamin D 2011, Food and Nutrition Board/Institute of Medicine, National Academies Press, Washington, DC.
12. Gafni R.I., Hazra R., Reynolds J.C., Maldarelli F., Tullio A.N., DeCarlo E., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as a salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006, 118:e711-e718.
13. Mora S., Sala N., Bricalli D., Zuin G., Chiumello G., Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001, 15:1823-1829.
14. Silva H.G., Tórtora R.P., Farias M.L. Increased bone turnover during the third trimester of pregnancy and decreased bone mineral density after parturition in adolescents as compared to age-matched control patients. Gynecol Endocrinol 2005, 21:174-179.
15. Ramos J.T., Rojo P., Ruano C., González-Tomé M.I., Sanchez-Granados J., Vargas C., et al. Stability of osteopenia in HIV-infected children over time. Presented at the 11th Conference on Retrovirus and Opportunistic Infections 2004.
16. McComsey G., Leonard E. The effect of calcium and vitamin D on bone mineral density in HIV-infected children with osteoporosis. Presented at the 10th Conference on Retroviruses and Opportunistic Infections 2003.
17. Duvivier C., Kolta S., Assoumou L., Ghosn J., Rozenberg S., Murphy R.L., et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 23:817-824.
18. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
19. McComsey G.A., Kitch D., Daar E.S., Tierney C., Jahed N.C., Tebas P., et al. Bone mineral density and fractures in anti-retroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011, 203:1791-1801.
20. Brown T.T., McComsey G.A., King M.S., Qaqish R.B., Bernstein B.M., Da Silva B.A. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 15:554-561.
21. Bruera D., Luna N., David D.O., Bergoglio L.M., Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917-1923.
22. Hazra R., Gafni R.I., Maldarelli F., Balis F.M., Tullio A.N., DeCarlo E., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005, 116:e846-e854.
23. Jones S., Restrepo D., Kasowitz A., Korenstein D., Wallenstein S., Schneider A., et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19:913-918.
24. Purdy J.B., Gafni R.I., Reynolds J.C., Zeichner S., Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152:582-584.
25. Giacomet V., Mora S., Martelli L., Merlo M., Sciannanblo M., Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40:448-450.
26. Viganò A., Zuccotti G.V., Puzzovio M., Pivetti V., Zamproni I., Cerini C., et al. Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther 2010, 15:1053-1058.
27. Carr A., Miller J., Eisman J.A., Cooper D.A. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001, 15:703-709.
28. Cotter A.G., Powderly W.G. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 2011, 25:501-515.
29. Lips P., Van Schoor N.M. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011, 25:585-591.
30. Buchacz K., Rogol A.D., Lindsey J.C., Wilson C.M., Hughes M.D., Seage G.R., et al. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003, 33:56-65.
31. Jacobson D.L., Lindsey J.C., Gordon C.M., Moye J., Hardin D.S., Mulligan K., et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS 2010, 24:687-696.
32. Bianchi M.L. Osteoporosis in children and adolescents. Bone 2007, 41:486-495.
33. Mora S., Pitukcheewanont P., Kaufman F.R., Nelson J.C., Gilsanz V. Biochemical markers of bone turnover and the volume and density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14:1664-1671.
34. Özçakar L., Guven G.S., Unal S., Akinci A. Osteoporosis in Turkish HIV/AIDS patients: comparative analysis by dual energy X-ray absorptiometry and digital X-ray radiogrammetry. Osteoporos Int 2005, 16:1363-1367.
35. Bakker I., Twisk J.W., Mechelen W.V., Kemper H.C. Fat-free body mass is the most important body composition determinant of 10-yr longitudinal development of lumbar bone in adult men and women. J Clin Endocrinol Metab 2003, 88:2607-2613.
36. Reid I.R. Relationships among body mass, its components, and bone. Bone 2002, 31:547-555.
37. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007, 92:4522-4528.
38. Duran A.C., Almeida L.B., Segurado A.A., Jaime P.C. Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet 2008, 21:346-350.
39. Peters B.S., Dos Santos L.C., Fisberg M., Wood R.J., Martini L.A. Prevalence of vitamin D insufficiency in Brazilian adolescents. Ann Nutr Metab 2009, 54:15-21.